Skip to main content

Advertisement

SpringerLink
Log in

The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy

  • Health Economics and Quality of Life (M Harrison, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Glucocorticoids are often required for adequate control of inflammation in many serious inflammatory diseases; common indications for long-term treatment include polymyalgia rheumatica, giant cell arteritis, asthma and chronic obstructive pulmonary disease. Long-term glucocorticoid therapy is, however, associated with many adverse effects involving skin, gastro-intestinal, eye, skeletal muscle, bone, adrenal, cardio-metabolic and neuropsychiatric systems. This balance between benefits and risks of glucocorticoids is important for clinical practice and glucocorticoid-related adverse effects can significantly impair health-related quality of life. Understanding the nature and mechanisms of glucocorticoid-related adverse effects may inform how patients are monitored for toxicity and identify those groups, such as older people, that may need closer monitoring. For clinical trials in diseases commonly treated with glucocorticoids, standardised measurement of glucocorticoid-related adverse effects would facilitate future evidence synthesis and meta-analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance;•• Of major importance

  1. Hench P. Effects of cortisone in the rheumatic diseases. Lancet. 1950;2(6634):483–4.

    CAS  PubMed  Google Scholar 

  2. Smolen, J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.

  3. Sarnes E et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–32.

    Article  PubMed  Google Scholar 

  4. Kirkham JJ et al. Can a core outcome set improve the quality of systematic reviews?—a survey of the Co-ordinating editors of Cochrane review groups. Trials. 2013;14:21.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Boers M et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014;67(7):745–53.

    Article  PubMed  Google Scholar 

  6. Chen YF et al. Scientific hypotheses can be tested by comparing the effects of one treatment over many diseases in a systematic review. J Clin Epidemiol. 2014;67(12):1309–19.

    Article  PubMed  Google Scholar 

  7. Sheu HM et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136(6):884–90.

    Article  CAS  PubMed  Google Scholar 

  8. Schoepe S et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.

    Article  CAS  PubMed  Google Scholar 

  9. Newell-Price J et al. Cushing’s syndrome. Lancet. 2006;367(9522):1605–17.

    Article  CAS  PubMed  Google Scholar 

  10. Schäcke H, Döcke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.

    Article  PubMed  Google Scholar 

  11. Tiganescu A et al. 11β-Hydroxysteroid dehydrogenase blockade prevents age-induced skin structure and function defects. J Clin Invest. 2013;123(7):3051–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Kerscher MJ, Korting HC. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis. Skin Pharmacol. 1992;5(2):77–80.

    Article  CAS  PubMed  Google Scholar 

  13. Curtis JR et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–6.

    Article  Google Scholar 

  14. Vinding GR et al. Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology. 2014;228(3):261–8.

    Article  CAS  PubMed  Google Scholar 

  15. Van der Goes MC et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913–9.

    Article  PubMed  Google Scholar 

  16. Storms WW, Theen C. Clinical adverse effects of inhaled corticosteroids: results of a questionnaire survey of asthma specialists. Ann Allergy Asthma Immunol. 1998;80(5):391–4.

    Article  CAS  PubMed  Google Scholar 

  17. Andrews RC et al. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002;87(12):5587–93.

    Article  CAS  PubMed  Google Scholar 

  18. Quondamatteo F. Skin and diabetes mellitus: what do we know? Cell Tissue Res. 2014;355(1):1–21.

    Article  PubMed  Google Scholar 

  19. Makrantonaki E, Zouboulis CC. Molecular mechanisms of skin aging: state of the art. Ann N Y Acad Sci. 2007;1119:40–50.

    Article  CAS  PubMed  Google Scholar 

  20. Aschoff R et al. Evaluation of the atrophogenic potential of hydrocortisone 1 % cream and pimecrolimus 1 % cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832–6.

    Article  CAS  PubMed  Google Scholar 

  21. Schoepe S, Schacke H, Asadullah K. Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. Dermatoendocrinol. 2011;3(3):175–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Norsgaard H et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hooten J, Hall 3rd R, Cardones A. Updates on the management of autoimmune blistering diseases. Skin Ther Lett. 2014;19(5):1–6.

    Google Scholar 

  24. Schacke H et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009;158(4):1088–103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Sen CK et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763–71.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Nagareddy PR et al. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol. 2005;289(5):H2144–52.

    Article  CAS  PubMed  Google Scholar 

  27. Holmes CJ et al. Dynamic role of host stress responses in modulating the cutaneous microbiome: implications for wound healing and infection. Adv Wound Care (New Rochelle). 2015;4(1):24–37.

    Article  Google Scholar 

  28. Da Silva JA et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–93. Epub 2005 Aug 17.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Gosain A, DiPietro LA. Aging and wound healing. World J Surg. 2004;28(3):321–6.

    Article  PubMed  Google Scholar 

  30. Brubaker AL et al. Reduced neutrophil chemotaxis and infiltration contributes to delayed resolution of cutaneous wound infection with advanced age. J Immunol. 2013;190(4):1746–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Saag KG et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med. 1994;96(2):115–23.

    Article  CAS  PubMed  Google Scholar 

  32. van der Goes MC et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015–21.

    Article  PubMed  Google Scholar 

  33. Helliwell T, Hider SL, Mallen CD. Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice. Br J Gen Pract. 2013;63(610):e361–6.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Carli L et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071–3.

    Article  CAS  PubMed  Google Scholar 

  35. Prokofyeva E, Wegener A, Zrenner E. Cataract prevalence and prevention in Europe: a literature review. Acta Ophthalmologica. 2013;91(5):395–405.

    Article  PubMed  Google Scholar 

  36. Rasanen P et al. Cost-utility of routine cataract surgery. Health Qual Life Outcomes. 2006;4:74.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47(4):171–88.

    Article  PubMed  Google Scholar 

  38. Huscher D et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–24.

    Article  CAS  PubMed  Google Scholar 

  39. Hoes JN et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Mosca M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Lane RJM, Mastaglia FL. Drug-induced myopathies in man. Lancet. 1978;312(8089):562–6.

    Article  Google Scholar 

  42. Schakman O et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol. 2013;45(10):2163–72.

    Article  CAS  PubMed  Google Scholar 

  43. Jover JA et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone, a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.

    Article  CAS  PubMed  Google Scholar 

  44. Mazlumzadeh M et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8.

    Article  CAS  PubMed  Google Scholar 

  45. Spiera RF et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.

    CAS  PubMed  Google Scholar 

  46. Gabriel SE et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873–8.

    Article  CAS  PubMed  Google Scholar 

  47. Khaleeli AA et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18(2):155–66.

    Article  CAS  Google Scholar 

  48. Levin OS et al. Steroid myopathy in patients with chronic respiratory diseases. J Neurol Sci. 2014;338(1–2):96–101.

    Article  CAS  PubMed  Google Scholar 

  49. Hosono, O., et al. Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy—comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging. Modern Rheumatology, 2014. 25(2):1–7.

  50. Batchelor TT et al. Steroid myopathy in cancer patients. Neurology. 1997;48(5):1234–8.

    Article  CAS  PubMed  Google Scholar 

  51. Pereira RMR, de Carvalho JF. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41–4.

    Article  CAS  PubMed  Google Scholar 

  52. LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardpulm Rehabil. 1997;17(2):76–84.

    Article  CAS  Google Scholar 

  53. Horber FF et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61(1):83–8.

    Article  CAS  PubMed  Google Scholar 

  54. Hansen M et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Laan RF et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119(10):963–8.

    Article  CAS  PubMed  Google Scholar 

  56. Nikitovic M et al. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659–69.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Rizzoli, R. and E. Biver, Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol, 2014.

  58. Compston J et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013;75(4):392–6. Provides guidelines for the management of osteoporosis.

  59. Grossman JM et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515–26.

    Article  Google Scholar 

  60. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011;365(1):62–70.

    Article  CAS  PubMed  Google Scholar 

  61. Ton FN et al. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464–70.

    Article  CAS  PubMed  Google Scholar 

  62. den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233–40.

    Article  CAS  Google Scholar 

  63. Hofbauer LC, Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol. 2009;23(10):1525–31.

    Article  CAS  PubMed  Google Scholar 

  64. Albaum JM et al. Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol. 2014;21(3):e486–504.

    PubMed  Google Scholar 

  65. Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013;34(9):518–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011;78(11):748–56.

    Article  PubMed  Google Scholar 

  67. Unizony, S., et al. Inpatient complications in patients with giant cell arteritis: decreased mortality and increased risk of thromboembolism, delirium and adrenal insufficiency. Rheumatology (Oxford), 2015.

  68. Jamilloux Y et al. Recovery of adrenal function after long-term glucocorticoid therapy for giant cell arteritis: a cohort study. PLoS ONE. 2013;8(7):e68713.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Kirwan JR et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1415–21.

    Article  CAS  PubMed  Google Scholar 

  70. Duru, N., et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013: 1–9. Provides EULAR recommendations for managing patients on medium-high-dose glucocorticoid therapy.

  71. Gruvstad E et al. Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Int J Clin Pharmacol Ther. 2014;52(1):15–26. doi:10.5414/CP201938.

    Article  CAS  PubMed  Google Scholar 

  72. Kazlauskaite R et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245–53.

    Article  CAS  PubMed  Google Scholar 

  73. Liu D et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. Provides practical guidance for clinicians for monitoring and managing glucocorticoid-related adverse effects.

  74. Ferris HA, Kahn CR. New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest. 2012;122(11):3854–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  75. Mazziotti G, Gazzaruso C, Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab. 2011;22(12):499–506.

    Article  CAS  PubMed  Google Scholar 

  76. Nwaneri, C., H. Cooper, and D. Bowen-Jones, Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes & Vascular Disease, 2013.

  77. Wassenberg S et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(11):3371–80.

    Article  CAS  PubMed  Google Scholar 

  78. van Everdingen AA et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136(1):1–12.

    Article  PubMed  Google Scholar 

  79. Ha Y et al. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus. 2011;20(10):1027–34.

    Article  CAS  PubMed  Google Scholar 

  80. Dasgupta B et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49(1):186–90.

    Article  Google Scholar 

  81. Dasgupta B et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.

    Article  Google Scholar 

  82. Hancock AT et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014;186(13):E495–501.

    Article  PubMed Central  PubMed  Google Scholar 

  83. Uddhammar A et al. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol. 2002;29(4):737–42.

    PubMed  Google Scholar 

  84. Aviña-Zubieta JA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology. 2013;52(1):68–75.

    Article  PubMed  Google Scholar 

  85. Mazzantini M et al. Adverse events during long-term low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol. 2012;39(3):552–7.

    Article  CAS  PubMed  Google Scholar 

  86. Hafström I et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis—a randomized study. J Rheumatol. 2007;34(9):1810–6.

    PubMed  Google Scholar 

  87. Hafner F et al. Endothelial function and carotid intima-media thickness in giant-cell arteritis. Eur J Clin Investig. 2014;44(3):249–56.

    Article  Google Scholar 

  88. Souverein PC et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Tomasson G et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160(2):73–80.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Kirwan J et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis. 2004;63(6):688–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Bakker MF et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–39.

    Article  PubMed  Google Scholar 

  92. Hoes JN et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.

    Article  CAS  PubMed  Google Scholar 

  93. Reynolds RM et al. Glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh type 2 diabetes study. Eur J Endocrinol. 2012;166(5):861–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  94. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–7.

    Article  CAS  PubMed  Google Scholar 

  95. Ninan J et al. Mortality in patients with biopsy-proven giant cell arteritis: a south Australian population-based study. J Rheumatol. 2011;38(10):2215–7.

    Article  PubMed  Google Scholar 

  96. Nadkarni S et al. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression. Circ Res. 2014;114(2):242–8.

    Article  CAS  PubMed  Google Scholar 

  97. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.

    Article  CAS  PubMed  Google Scholar 

  98. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.

    Article  PubMed  Google Scholar 

  99. Harrison MJ et al. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol. 2008;35(4):592–602.

    PubMed  Google Scholar 

  100. Buitinga L et al. Comparative responsiveness of the EuroQol-5D and short form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry. Arthritis Care Res. 2012;64(6):826–32.

    Article  Google Scholar 

  101. Gaujoux-Viala C et al. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(9):1478–83.

    Article  PubMed  Google Scholar 

  102. Marra CA et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60(7):1571–82.

    Article  PubMed  Google Scholar 

  103. Moller A, Sartipy U. Long-term health-related quality of life following surgery for lung cancer. Eur J Cardiothorac Surg. 2012;41(2):362–7. Demonstrates EQ-5D is responsive to AEs.

  104. Brazier J, Tsuchiya A. Preference-based condition-specific measures of health: what happens to cross programme comparability? Health Econ. 2010;19(2):125–9.

    Article  PubMed  Google Scholar 

  105. NICE, Guide to the methods of technology appraisal 2013. Process and methods guides. 2013: London, UK.

  106. Heather EM et al. Including adverse drug events in economic evaluations of anti-tumour necrosis factor-alpha drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models. Pharmacoeconomics. 2014;32(2):109–34.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Emma Harris, Ana Tiganescu, Sandy Tubeuf and Sarah Louise Mackie declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, St James’s University Hospital, University of Leeds, Wellcome Trust Brenner Building, Leeds, LS9 7TF, UK

    Emma Harris & Ana Tiganescu

  2. Leeds Institute of Health Sciences, University of Leeds, Charles Thackrah Building, Leeds, LS2 9JT, UK

    Sandy Tubeuf

  3. Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, University of Leeds and the Leeds Teaching Hospitals NHS Trust, Leeds, LS7 4SA, UK

    Sarah Louise Mackie

Authors
  1. Emma Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Tiganescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandy Tubeuf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah Louise Mackie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Louise Mackie.

Additional information

This article is part of the Topical Collection on Health Economics and Quality of Life

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harris, E., Tiganescu, A., Tubeuf, S. et al. The Prediction and Monitoring of Toxicity Associated with Long-Term Systemic Glucocorticoid Therapy. Curr Rheumatol Rep 17, 38 (2015). https://doi.org/10.1007/s11926-015-0513-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0513-4

Keywords

Search

Navigation